On Oct. 9, the U.S. Senate passed the BIOSECURE Act as an amendment to the National Defense Authorization Act (NDAA). The legislation prohibits federal agencies from contracting with companies of concern that provide biotechnology equipment or services, or from contracting with any entity that uses such equipment or services. “Biotechnology companies of concern” are those deemed to be national security risks due to links to foreign adversaries. The legislation may affect the ability of pharmaceutical companies that contract with the federal government to obtain active pharmaceutical ingredients from certain Chinese entities.
BIOSECURE Act Advances in the US Senate
